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Cost-effectiveness of urine-based tuberculosis screening in 
hospitalised patients with HIV in Africa: a microsimulation 
modelling study
Krishna P Reddy, Ankur Gupta-Wright, Katherine L Fielding, Sydney Costantini, Amy Zheng, Elizabeth L Corbett, Liyang Yu, Joep J van Oosterhout, 
Stephen C Resch, Douglas P Wilson, C Robert Horsburgh Jr, Robin Wood, Melanie Alufandika-Moyo, Jurgens A Peters, Kenneth A Freedberg, 
Stephen D Lawn*, Rochelle P Walensky
Summary
Background Testing urine improves the number of tuberculosis diagnoses made among patients in hospital with HIV. 
In conjunction with the two-country randomised Rapid Urine-based Screening for Tuberculosis to Reduce AIDS-
related Mortality in Hospitalised Patients in Africa (STAMP) trial, we used a microsimulation model to estimate the 
effects on clinical outcomes and the cost-effectiveness of adding urine-based tuberculosis screening to sputum 
screening for hospitalised patients with HIV.
Methods We compared two tuberculosis screening strategies used irrespective of symptoms among hospitalised 
patients with HIV in Malawi and South Africa: a GeneXpert assay (Cepheid, Sunnyvale, CA, USA) for 
Mycobacterium tuberculosis and rifampicin resistance (Xpert) in sputum samples (standard of care) versus sputum 
Xpert combined with a lateral flow assay for M tuberculosis lipoarabinomannan in urine (Determine TB-LAM Ag test, 
Abbott, Waltham, MA, USA [ formerly Alere]; TB-LAM) and concentrated urine Xpert (intervention). A cohort of 
simulated patients was modelled using selected characteristics of participants, tuberculosis diagnostic yields, and use 
of hospital resources in the STAMP trial. We calibrated 2-month model outputs to the STAMP trial results and 
projected clinical and economic outcomes at 2 years, 5 years, and over a lifetime. We judged the intervention to be 
cost-effective if the incremental cost-effectiveness ratio (ICER) was less than US$750/year of life saved (YLS) in 
Malawi and $940/YLS in South Africa. A modified intervention of adding only TB-LAM to the standard of care was 
also evaluated. We did a budget impact analysis of countrywide implementation of the intervention.
Findings The intervention increased life expectancy by 0·5–1·2 years and was cost-effective, with an ICER of $450/YLS 
in Malawi and $840/YLS in South Africa. The ICERs decreased over time. At lifetime horizon, the intervention 
remained cost-effective under nearly all modelled assumptions. The modified intervention was at least as cost-
effective as the intervention (ICERs $420/YLS in Malawi and $810/YLS in South Africa). Over 5 years, the intervention 
would save around 51 000 years of life in Malawi and around 171 000 years of life in South Africa. Health-care 
expenditure for screened individuals was estimated to increase by $37 million (10·8%) and $261 million (2·8%), 
respectively.
Interpretation Urine-based tuberculosis screening of all hospitalised patients with HIV could increase life expectancy 
and be cost-effective in resource-limited settings. Urine TB-LAM is especially attractive because of high incremental 
diagnostic yield and low additional cost compared with sputum Xpert, making a compelling case for expanding its 
use to all hospitalised patients with HIV in areas with high HIV burden and endemic tuberculosis.
Funding UK Medical Research Council, UK Department for International Development, Wellcome Trust, US National 
Institutes of Health, Royal College of Physicians, Massachusetts General Hospital.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Tuberculosis is the leading cause of death among the 
25 million people with HIV in sub-Saharan Africa.1 In 
post-mortem studies, tuberculosis accounts for ap-
proximately 40% of hospital deaths among people with 
HIV, but is undiagnosed before death in nearly half of 
these patients.2,3 Many tuberculosis tests have poor 
sensitivity and long turnaround times, and obtaining 
suitable specimens for sputum tests can be difficult. 
Testing urine with a lateral flow assay for Mycobacterium 
tuberculosis lipoarabinomannan (Determine TB-LAM 
Ag test, Abbott, Waltham, MA, USA [ formerly Alere]; 
TB-LAM) or with the GeneXpert assay for M tuberculosis 
and rifampicin resistance (Cepheid, Sunnyvale, CA, 
USA; Xpert) increases tuberculosis diagnostic yield in 
hos pitalised patients with HIV.4–6
The Rapid Urine-based Screening for Tuberculosis to 
Reduce AIDS-related Mortality in Hospitalised Patients 
in Africa (STAMP) randomised trial in Malawi and 
South Africa evaluated tuberculosis screening with 
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sputum Xpert, urine TB-LAM, and concentrated urine 
Xpert among unselected hospitalised medical patients 
with HIV, irrespective of tuberculosis symptoms, 
compared with screening with sputum Xpert alone.7 
The addition of urine testing reduced 2-month all-
cause mortality by 2·8% and increased tuberculosis 
diagnoses by 7·3%. Among patients with CD4 counts 
lower than 100 cells per µL, urine testing decreased all-
cause mortality by 7·1%.8 A cost-effectiveness analysis 
was planned with the trial.7 Weighing additional 
tuberculosis cases detected and deaths prevented 
against additional costs of widespread testing is crucial 
in deciding whether to scale up urine tuberculosis 
screening in hospitals in resource-limited settings. We 
used STAMP trial results in a mathematical model to 
project clinical and economic outcomes and cost-
effectiveness of urine-based tuberculosis screening in 
hospitalised patients with HIV beyond the trial’s time 
horizon.
Methods
Study design
We adapted the Cost-Effectiveness of Preventing AIDS 
Complications-International (CEPAC-I) model, which is 
a validated microsimulation of HIV-related disease 
and treatment,9,10 to account for tuberculosis natural 
history, diagnosis, and treatment. We compared the 
two tuberculosis screening strategies assessed in the 
STAMP trial in simulated cohorts of unselected 
hospitalised patients with HIV in Malawi and South 
Africa: sputum Xpert (standard of care) versus sputum 
Xpert, TB-LAM, and concentrated urine Xpert (inter-
vention). In a post-hoc analysis, we also assessed a 
modified intervention of sputum Xpert and TB-LAM 
without urine Xpert.11 To attain stable per-person results, 
models were run on cohorts of 1 million hospitalised 
patients with HIV in Malawi and South Africa. We 
populated the model with cohort characteristics, 
tuberculosis diagnostic yields, and data on use of hospital 
Research in context
Evidence before this study
We searched PubMed for studies that investigated the cost-
effectiveness of urine lipoarabinomannan assay (Determine 
TB-LAM Ag test [TB-LAM], Abbott, Waltham, MA, USA 
[formerly Alere]) for tuberculosis diagnosis published from 
Jan 1, 2000, to Jan 31, 2018. We combined the search terms 
“lipoarabinomannan”, “LAM”, and “urine LAM” with 
“tuberculosis” and with “cost-effectiveness”, “economic”, 
or “model”. We identified two cost-effectiveness analyses, 
published before the Rapid Urine-based Screening for 
Tuberculosis to Reduce AIDS-related Mortality in Hospitalised 
Patients in Africa (STAMP) randomised trial and another 
multicountry randomised trial of TB-LAM in hospitalised 
patients with HIV were completed. The analyses focused on use 
of TB-LAM in patients with HIV who had symptoms of 
tuberculosis. We found no previous cost-effectiveness analyses 
of TB-LAM use in unselected patients with HIV. Testing urine 
with the GeneXpert assay for Mycobacterium tuberculosis and 
rifampicin resistance (Cepheid, Sunnyvale, CA, USA; Xpert) and 
TB-LAM increases diagnostic yield in people with HIV, 
particularly those with very low CD4 cell counts, symptoms 
suggestive of tuberculosis, or both. Model-based studies have 
shown that addition of urine TB-LAM testing to standard 
tuberculosis diagnostic strategies in people with HIV with low 
CD4 cell counts and symptoms of tuberculosis is cost-effective. 
However, many people with HIV and tuberculosis have atypical 
symptoms, and CD4 cell count might not be readily available in 
the acute hospital setting. The STAMP trial assessed the clinical 
benefit of urine tuberculosis screening in unselected 
hospitalised patients with HIV, regardless of CD4 cell count, 
tuberculosis symptoms, or suspicion of tuberculosis. 
The addition of TB-LAM and urine Xpert to sputum Xpert 
increased the number of tuberculosis diagnoses. No 
cost-effectiveness or budget impact analysis of such a 
widespread screening strategy had been done previously. 
Urine tests add costs and would have the greatest impact in 
settings with severe resource constraints. We have now used 
modelling to critically weigh long-term clinical benefits against 
costs.
Added value of this study
We adapted a mathematical model that was calibrated to 
STAMP trial outcomes, and validated with longer-term 
outcomes from other published studies, to project clinical and 
economic outcomes, cost-effectiveness, and budget impact of 
adding TB-LAM and concentrated urine Xpert to standard 
sputum Xpert tuberculosis screening in unselected hospitalised 
patients with HIV in Malawi and South Africa. The addition of 
urine-based screening was projected to increase life expectancy 
and be cost-effective across a wide range of scenarios in both 
countries. Urine screening countrywide could improve clinical 
outcomes and have modest budget impact due mostly to 
prolonged survival.
Implications of all the available evidence
WHO recommends restricting urine TB-LAM testing to 
hospitalised patients with HIV and very low CD4 cell counts, 
and uptake has been slow. By extending the time horizon of the 
STAMP trial, our results suggest that substantial clinical benefits 
could be achieved with economic efficiency by expanding 
urine-based screening to all hospitalised patients with HIV in 
tuberculosis-endemic settings, regardless of CD4 cell count. 
The consistency of our results in a low-income and a 
middle-income country signal generalisability across settings 
with varying degrees of resource availability. With these clinical 
benefits, rapid testing times, and little additional cost, urine 
TB-LAM testing is particularly attractive as a strategy to reduce 
the huge burden of tuberculosis-related deaths in people 
with HIV.
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resources derived from the STAMP trial. We obtained 
additional natural history and treatment data from 
published studies to project outcomes beyond the STAMP 
trial’s 2-month time horizon.
The primary outcome for this analysis was the 
incremental cost-effectiveness ratio (ICER), which was 
calculated as the difference between intervention and 
standard of care groups in lifetime health-care costs 
(2017 US$) divided by the difference in life expectancy. 
Second-line antiretroviral therapy (ART) is featured 
in national HIV care guidelines for Malawi and 
South Africa.12,13 Therefore, to set relevant cost-effectiveness 
thresholds for our primary analysis, we used the CEPAC-I 
model to determine the ICER of a care strategy that 
included second-line ART (after failure of first-line ART) 
compared with a strategy that did not include second-line 
ART. This analysis yielded ICERs of $750 per year of life 
saved (YLS) in Malawi and $940 per YLS in South Africa. 
We additionally projected all-cause mortality, life-years 
accrued, costs, and cost-effectiveness over 2-year and 
5-year time horizons. We report undiscounted outcomes 
for clinical and budget evaluations and outcomes 
discounted by 3% per year for the cost-effectiveness anal-
ysis, as recommended by the Second Panel on Cost-
Effectiveness in Health and Medicine.14
Model overview
Each simulated hospitalised patient with HIV who was 
entered into the model was followed up monthly from 
tuberculosis screening to death, counting all years of life 
and lifetime costs of tuberculosis and HIV care. Patients’ 
characteristics were created by the model by randomly 
selecting from the STAMP-informed characteristics 
(eg, CD4 cell count, tuberculosis status). Clinical out-
comes were tracked as each individual transitioned 
through different states of tuberculosis and HIV disease 
progression and treatment (appendix).9,10
We assumed that tuberculosis test turnaround time 
and the starting of treatment for any positive result 
would occur within 1 month of the patient entering the 
model. As in STAMP and real practice, tuberculosis 
could also be diagnosed clinically, without microbiological 
confirmation, and lead to empirical treatment. Each 
tuberculosis treatment regimen has a probability of 
success, given regimen efficacy (appendix). All simulated 
individuals were classified as being eligible for ART12,13 
and were modelled as either already taking therapy 
before hospitalisation or starting it within 1 month 
of entry into the model. ART-adherent individuals were 
assumed to have a decrease in HIV-related morbidity 
and mortality.9,10 We accounted for non-adherence after 
leaving hospital and loss to follow-up from care.
Model validation
To validate the outcomes of this analysis, we calibrated 
model-generated 2-month mortality to STAMP trial 
results by adjusting tuberculosis-related mortality and 
non-tuberculosis HIV-related mortality. The STAMP trial 
did not differentiate between causes of death, and we 
report only all-cause mortality. Published long-term 
cohort studies of mortality in people with HIV are largely 
limited to outpatients starting ART, who are generally 
less ill than STAMP participants. Thus, for external 
validation, we compared results from a modelled cohort 
Malawi South Africa References
Characteristics of patients with HIV
Median (IQR) age (years) 38 (32–47) 37 (30–46) STAMP
Proportion of men (%) 37% 50% STAMP
Proportion of women (%) 63% 50% STAMP
Median (IQR) CD4 count at admission (cells per µL) 219 (86–431) 236 (70–445) STAMP
Patients taking ART at admission 78% 64% STAMP
Median (range*) underlying tuberculosis prevalence† 23·5% (10–50) 28·5% (10–50) STAMP, 15
Median (range*) number of patients able to provide 
sputum samples
39% (20–100) 75% (20–100) STAMP
Median (range) probability of empirical treatment*‡ 4% (0–40) 10% (0–40) STAMP
Monthly probability of tuberculosis infection based 
on age (%)
0·4–0·8 0·4–0·8 16
Screening strategy diagnostic yield for CD4 count <100 vs ≥100 cells per µL§
Standard of care (sputum Xpert)¶ 19% and 18% 31% and 29% STAMP
Intervention (range*) 77% and 72% 
(40–90%)
56% and 52% 
(40–90%)
STAMP
Modified intervention (sputum Xpert and TB-LAM) 74% and 69% 51% and 47% STAMP
Resource use
Median length of hospitalisation (days) 5 7 STAMP
Hospital bed cost per day (US$) $1 $56 17
Additional hospital resource use cost per admission 
(US$)||
$23 $98 STAMP, 
18–20
Median (range) costs per test for tuberculosis diagnostic assays (US$)**
Sputum Xpert†† $25 ($5–35) $15 ($5–35) 18,19
TB-LAM $3 ($2–8) $3 ($2–8) 21
Urine Xpert††‡‡ $26 ($6–36) $15 ($5–35) 18,19
Costs of treatment (US$)§§
Drug-susceptible tuberculosis treatment cost 
per month for 6 months
$7 $7 22
Multidrug-resistant tuberculosis treatment 
per month for 24 months
$231 $231 22
First-line ART per month $11 $11 23
Values are calculated in 2017 US$. STAMP=Rapid Urine-based Screening for Tuberculosis to Reduce AIDS-related 
Mortality in Hospitalised Patients in Africa randomised trial. ART=antiretroviral therapy. Xpert=GeneXpert assay 
for Mycobacterium tuberculosis and rifampicin resistance. TB-LAM=lateral flow urine assay for M tuberculosis 
lipoarabinomannan. *Range values were assessed in sensitivity analysis. †Calculated as 1·25 times the number of 
microbiologically confirmed cases15 plus the number of clinically diagnosed cases (ie, without microbiological 
confirmation), divided by the study population size (all in the intervention group). ‡In patients diagnosed clinically 
without microbiological confirmation, within 1 month in the model rather than during hospitalisation in the 
STAMP trial. §The diagnostic yields applied in the model accounted for non-provision of sputum specimens and for 
concordance between test results (ie, adding a second test would increase diagnostic yield only if it detected additional 
tuberculosis cases not detected by the first test). ¶ The diagnostic yield of sputum Xpert is slightly higher among 
patients with CD4 counts <100 cells per µL, despite lower sensitivity, because of higher sputum provision in this 
subgroup. ||Excludes costs of tuberculosis diagnostic tests assessed in STAMP. **Diagnostic test costs include personnel 
time. ††Xpert cost in a Malawi-specific costing study was higher than the cost reported in South African studies and by 
the South Africa National Health Laboratory Service19 due to different costs of maintenance and repair and different 
economies of scale. ‡‡Urine Xpert costs were slightly higher than those of sputum Xpert because of the centrifugation 
needed to concentrate the urine specimen. Cost differences are not apparent in South Africa due to rounding. 
§§Because tuberculosis and ART drugs are imported across countries, we assumed that costs were equal across 
countries. Costs shown here are for drugs only. 
Table 1: Model input parameters
See Online for appendix
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of ambulatory people with HIV starting ART against 
published outcomes (appendix).
Input parameters
As in STAMP, the initial median CD4 counts in the model 
were set to 219 cells per µL in Malawi and 236 cells per µL 
in South Africa (table 1). Given the imperfect diagnostic 
yields of the tests, we assumed that the underlying 
tuberculosis prevalence at each site was 1⋅25 times the 
number of cases confirmed microbiologically by sputum 
Xpert, TB-LAM, or urine Xpert plus the number of 
clinically diagnosed cases, all in the intervention group, 
divided by the total number of participants in the 
intervention group (appendix). The estimated prevalence 
was 23·5% in Malawi and 28·5% in South Africa, and 
these values were consistent with previous reports.4–6,24 
Based on rifampicin resistance data among STAMP 
participants who underwent Xpert testing, we assumed 
that among the model patients with tuberculosis, 1% in 
Malawi and 3% in South Africa had multidrug-resistant 
disease.
Diagnostic yields of individual and combinations of 
tests, stratified by CD4 count (<100 cells per µL or 
≥100 cells per µL), were based on STAMP results and our 
tuberculosis prevalence estimates (table 1). Overall 
diagnostic yields in Malawi and South Africa were 
18% and 30% for the standard of care and 73% and 
53% for the intervention. Because all positive results in 
STAMP were classified as true positives, we applied 
published test specificity (table 2).4,5,25–27 Informed by 
STAMP, in the base case in Malawi and South Africa, the 
probability of patients being able to provide a sputum 
sample was set to 39% and 75%, respectively. We 
assumed that all model patients in the intervention 
group had urine samples available. Also informed 
by STAMP, we assumed that 4% of model patients in 
Malawi and 10% of those in South Africa were diagnosed 
clinically and treated empirically for tuberculosis. 
Clinical diagnoses accounted for a greater proportion of 
overall tuberculosis diagnoses in the standard of care 
group than in the intervention group (56% vs 26%).
The parameters for tuberculosis treatment outcomes 
were set on the basis of previous studies (appendix). HIV 
treatment parameters were applied as in previous African 
CEPAC-I studies (appendix).9,10
Data on resource use, including number of diagnostic 
tests done and drugs consumed in the hospital, were 
collected from a subset of STAMP participants at each 
site.7 To approximate average hospitalisation costs, we 
multiplied length of stay (median 5 days in Malawi and 
7 days in South Africa) by the daily cost of hospitalisation 
and then added the average quantities (and associated 
costs) of resources,28 for which we obtained costs from 
country-specific costing studies and national laboratory 
listings (appendix).18–20,22,23,29 The costs of sputum Xpert, 
TB-LAM, and concentrated urine Xpert were $25, $3, 
and $26, respectively, in Malawi and $15, $3, and $15, 
respectively, in South Africa (table 1). We included costs 
after discharge from hospital, including those of 
tuberculosis and HIV care (appendix).
Sensitivity and alternative scenario analyses
To assess cost-effectiveness beyond the STAMP trial and in 
accordance with variation reported in other settings, 
we assessed uncertainty with one-way and multiway 
deterministic sensitivity analyses.30 We used the following 
ranges: tuberculosis prevalence 10–50%; probability of 
patients being able to provide a sputum sample 20–100%; 
probability of empirical tuberculosis treatment 0–40%; 
sputum Xpert sensitivity within 20% of the base case; 
diagnostic yields of the intervention 40–90%; and cost of 
tuberculosis tests $5–35 for sputum and urine Xpert (plus 
urine centrifugation cost) and $2–8 for TB-LAM. We also 
assessed cost-effectiveness at different time horizons 
(2-year and 5-year horizons in addition to lifetime horizon).
We evaluated scenarios that used an alternative target 
population or testing strategy. First, we did a subgroup 
analysis (which was prespecified in STAMP) among 
individuals with CD4 counts less than 100 cells per µL. 
Second, because policy makers have been considering a 
strategy that adds only TB-LAM to the standard of care,11 
we analysed a modified intervention that added only 
TB-LAM to sputum Xpert.
Budget impact analysis
We did a budget impact analysis of national 
implementation of the intervention or modified 
Sensitivity Specificity References
Sputum Xpert
CD4 count <100 cells 
per µL
40% (20–60)* 99% STAMP, 25
CD4 count ≥100 cells 
per µL
43% (23–63)* 99% STAMP, 25
Urine TB-LAM
CD4 count <100 cells 
per µL
53% 96% STAMP, 5,26,27
CD4 count ≥100 cells 
per µL
42% 98% STAMP, 5,26,27
Urine Xpert
CD4 count <100 cells 
per µL
31% 99% STAMP, 4
CD4 count ≥100 cells 
per µL
13% 99% STAMP, 4
The indicated sensitivity of each test is the sensitivity among individuals in the 
STAMP trial who provided a specimen and is independent of other test results. 
In the model, diagnostic yields instead of sensitivities were used for multitest 
strategies to better reflect concordance between tests and incremental diagnostic 
yields. In multitest strategies the lowest specificity of any individual test was 
applied, as informed by previously published studies. Xpert=GeneXpert assay for 
Mycobacterium tuberculosis and rifampicin resistance. STAMP=Rapid Urine-based 
Screening for Tuberculosis to Reduce AIDS-related Mortality in Hospitalised 
Patients in Africa randomised trial. TB-LAM=lateral flow urine assay for 
M tuberculosis lipoarabinomannan. *Ranges (shown in brackets) were assessed 
in sensitivity analyses.
Table 2: Tuberculosis diagnostic assay performance characteristics
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intervention instead of the standard of care in Malawi 
and South Africa for all hospitalised patients with 
HIV over a 2-year and 5-year period. We assumed 
that in Malawi and South Africa, respectively, 
70 000 and 500 000 people with HIV would be admitted 
to hospital annually, and we applied model-generated 
per-person clinical and economic projections 
(appendix).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, 
writing of the report, or the decision to submit the 
paper for publication. The corresponding author had 
full access to all the data in the study and had final 
responsibility for the decision to submit the paper for 
publication.
Results
The intervention improved tuberculosis diagnostic yield 
compared with the standard of care, with absolute 
increases of 55% in Malawi and 23% in South Africa. 
Model-generated 2-month all-cause mortality results 
matched those in the STAMP trial to within 0·1% when 
stratified by country and study group, and when limited 
to patients with CD4 counts less than 100 cells per µL, 
also stratified by country and study group (appendix). In 
Malawi, model-projected all-cause mortality in the 
intervention group was reduced at 2 months, 2 years, and 
5 years compared with the standard of care group 
(table 3). In South Africa, the intervention was associated 
with reduced mortality at all timepoints, but to a lesser 
degree (table 3). The intervention increased undiscounted 
life expectancy by 1·2 years in Malawi and 0·5 years in 
South Africa compared with the standard of care (table 3).
Mortality Lifetime outcomes
2 months 2 years 5 years Life-years
(undiscounted)
Life-years 
(discounted)*
Cost (US$; 
discounted)*†
ICER (US$/YLS; 
discounted)†‡
Intervention in all patients (sputum Xpert, urine TB-LAM, and concentrated urine Xpert)
Malawi
Standard of care 24·4% 40·7% 50·5% 12·5 8·4 3450 ··
Intervention 20·9% 35·2% 45·8% 13·7 9·1 3790 450
South Africa
Standard of care 17·7% 32·0% 42·4% 14·1 9·5 8500 ··
Intervention 15·5% 29·6% 40·4% 14·6 9·8 8770 840
Intervention in patients with CD4 counts <100 cells per µL (sputum Xpert, urine TB-LAM, and concentrated urine Xpert)
Malawi
Standard of care 40·5% 65·2% 75·6% 6·3 4·3 2090 ··
Intervention 33·7% 58·5% 70·6% 7·6 5·2 2500 490
South Africa
Standard of care 32·2% 55·9% 67·8% 8·2 5·6 6920 ··
Intervention 23·9% 50·2% 63·7% 9·2 6·3 7630 1000
Modified intervention in all patients (sputum Xpert and urine TB-LAM)
Malawi
Standard of care 24·4% 40·7% 50·5% 12·5 8·4 3450 ··
Modified intervention 21·1% 35·5% 46·0% 13·6 9·1 3750 420
South Africa
Standard of care 17·7% 32·0% 42·4% 14·1 9·5 8500 ··
Modified intervention 16·0% 30·2% 41·0% 14·5 9·7 8690 810
Intervention vs modified intervention in all patients
Malawi
Modified intervention 21·1% 35·5% 46·0% 13·6 9·1 3750 ··
Intervention 20·9% 35·2% 45·8% 13·7 9·1 3790 910
South Africa
Modified intervention 16·0% 30·2% 41·0% 14·5 9·7 8690 ··
Intervention 15·5% 29·6% 40·4% 14·6 9·8 8770 930
Values are calculated in 2017 US$. ICER=incremental cost-effectiveness ratio. YLS=year of life saved. Xpert=GeneXpert assay for Mycobacterium tuberculosis and rifampicin 
resistance. TB-LAM=lateral flow urine assay for M tuberculosis lipoarabinomannan. *Discounted 3% per year. †Cost includes all health-care expenditures. ‡The ICER is the 
difference between the intervention and standard of care or between the modified intervention and standard of care in discounted costs divided by the difference in 
discounted life-years. The displayed life-years and costs are rounded, but the ICER was calculated with non-rounded life-years and costs. We considered the intervention or 
the modified intervention to be cost-effective if its ICER was less than the cost-effectiveness thresholds of $750/YLS in Malawi and $940/YLS in South Africa 
(the ICERs of including second-line antiretroviral therapy in these countries).
Table 3: Clinical and economic outcomes, including cost-effectiveness, of tuberculosis screening strategies among hospitalised people with HIV
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Hospitalisation costs per patient were $29 in Malawi and 
$491 in South Africa, including cumulative resource use 
and bed costs for the period in hospital, but excluding 
STAMP diagnostic test costs. Discounted per-person 
lifetime health-care costs in the standard of care and 
intervention groups in Malawi were $3450 and $3790, and 
in South Africa were $8500 and $8770. The ICER of the 
intervention compared with standard of care at a lifetime 
horizon was $450 per YLS in Malawi and $840 per YLS in 
South Africa, both of which were cost-effective (table 3). 
The intervention became cost-effective in Malawi by 
4 years and in South Africa by 15 years (figure 1).
The intervention was cost-effective across nearly all 
parameter variations, with ICERs generally changing by 
less than 10% from the base case in the sensitivity analyses 
(appendix). The only exception was when diagnostic yield 
of the intervention was set to 40% in South Africa. In a 
sensitivity analysis that varied the time horizon, sputum 
provision probability, and tuberculosis prevalence, the 
intervention was generally not cost-effective at 2 years but 
was cost-effective at 5 years and over a lifetime (figure 2). 
With a lifetime horizon, the intervention was cost-effective 
across nearly all values for empirical treatment probability 
and tuberculosis prevalence when simultaneously varied 
(appendix).
Among patients with CD4 counts less than 100 cells 
per µL, the intervention increased undiscounted life 
expectancy by 1·3 years in Malawi and 1·0 year in 
South Africa (table 3). The ICERs for the intervention in 
this subgroup were higher than those in the entire 
cohort, but the intervention remained cost-effective in 
Malawi and its ICER was slightly higher than the cost-
effectiveness threshold in South Africa.
With the modified intervention, undiscounted life 
expectancy increased by 1·1 years in Malawi and 0·4 years 
in South Africa compared with the standard of care, and it 
was at least as cost-effective as the STAMP intervention 
(table 3). As in the base case, the modified intervention 
became more cost-effective over time in both countries 
(figure 1). The ICER of the intervention compared with 
that of the modified intervention (ie, the incremental cost-
effectiveness of urine Xpert) was $910 per YLS in Malawi 
and $930 per YLS in South Africa (table 3, appendix). 
When limiting the comparison between the modified 
intervention and the standard of care to patients with CD4 
counts of less than 100 cells per µL, ICERs were 
$460 per YLS in Malawi and $990 per  YLS in South Africa, 
which were slightly higher than those among all patients 
(appendix).
Implementing the intervention nationally and scaled 
to all hospitalised patients with HIV over 5 years was 
associated with around 51 000 YLSs in Malawi 
(7·5% increase in life-years compared with standard of 
care) and 171 000 YLSs in South Africa (3·2% increase). 
TB-LAM and urine Xpert tests themselves, not including 
downstream changes in health-care expenditures, added 
$10 million to costs in Malawi and $47 million to costs in 
South Africa over 5 years. In Malawi, the intervention 
increased cumulative health-care expenditures among 
screened individuals by $10 million (11·2%) over 2 years 
and $37 million (10·8%) over 5 years. In South Africa, 
Figure 1: ICERs over time for different tuberculosis screening strategies among hospitalised people with HIV
ICERs are calculated compared with the standard of care (sputum Xpert). The intervention consists of sputum Xpert, 
a lateral flow assay of urine for M tuberculosis lipoarabinomannan, and concentrated urine Xpert. The strategy 
“Intervention CD4 count <100 cells per μL” is compared with sputum Xpert alone also done in patients with CD4 counts 
<100 cells per μL. The modified intervention consists of sputum Xpert and a lateral flow assay of urine for M tuberculosis 
lipoarabinomannan without urine Xpert. The country-specific ICER thresholds were calculated by comparing modelled 
care strategies that did and did not include second-line antiretroviral therapy. ICER=incremental cost-effectiveness 
ratio. Xpert=GeneXpert assay for Mycobacterium tuberculosis and rifampicin resistance alone. YLS=year of life saved.
Figure 2: ICERs for urine-based tuberculosis screening with varying sputum sample provision and prevalence 
of active tuberculosis, by different time horizons
ICERs for the intervention are calculated compared with the standard of care. ICER=incremental cost-effectiveness 
ratio. *ICER threshold for Malawi is US$750 per year of life saved, and for South Africa is $940 per year of life saved. 
Values below the thresholds are cost-effective.
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
0
1000
2000
3000
4000
5000
IC
ER
 (U
S$
/Y
LS
)
Time since hospital admission (years)
Intervention all patients, Malawi
Intervention all patients, South Africa
Intervention CD4 count <100 cells per μL, Malawi
Intervention CD4 count <100 cells per μL, South Africa
Modified intervention all patients, Malawi
Modified Intervention all patients, South Africa
ICER threshold, Malawi ($750/YLS)
ICER threshold, South Africa ($940/YLS)
10
20
30
40
50
Pr
ev
al
en
ce
 o
f a
ct
iv
e
tu
be
rc
ul
os
is 
(%
)
2 years 5 years Lifetime
Malawi
20 40 60 80 100
10
20
30
40
50
Pr
ev
al
en
ce
 o
f a
ct
iv
e
tu
be
rc
ul
os
is 
(%
)
Probability that patients could
provide a sputum sample (%)
20 40 60 80 100
Probability that patients could
provide a sputum sample (%)
20 40 60 80 100
Probability that patients could
provide a sputum sample (%)
South Africa
ICER above cost-effectiveness threshold*
ICER below cost-effectiveness threshold*
Base case
Articles
www.thelancet.com/lancetgh   Vol 7   February 2019 e206
health-care expenditures increased by $73 million (2·4%) 
over 2 years and $261 million (2·8%) over 5 years (figure 3). 
In Malawi, the largest contributors to the increase in 5-year 
health expenditures were tuberculosis diagnostic and 
treatment costs (each increased by 33%), and in South 
Africa the largest contributor was non-tuberculosis, non-
ART HIV care costs, which increased by 45% due to longer 
survival (figure 3). While still providing notable clinical 
benefit, the budget impact of the modified intervention 
was lower than that of the intervention (figure 3).
Discussion
With use of the CEPAC-I model to simulate the STAMP 
trial and project long-term outcomes, we found that 
screening unselected hospitalised patients with HIV for 
tuberculosis with TB-LAM and sputum and urine Xpert 
increased life expectancy by 0·5–1·2 years and was cost-
effective compared with sputum Xpert alone in Malawi 
and South Africa. This approach remained cost-effective 
in the sensitivity analyses intended to test generalisability 
beyond trial settings. Adding only TB-LAM to sputum 
Xpert in the modified intervention provided similar 
clinical benefit and was at least as cost-effective.
Access to primary STAMP trial data is a key strength of 
our analysis. Model structure and input parameters 
reflected those of the trial, and we calibrated 2-month all-
cause mortality results to those of the trial. Our analysis 
was done in two countries with very different health-care 
infrastructures, costs, and annual per-capita gross 
domestic products ($330 in Malawi and $6090 in 
South Africa in 2017).31 The intervention’s clinical and 
economic effects and ICERs varied between Malawi and 
South Africa mainly because of differences in the 
probability of obtaining a sputum sample, diagnostic 
yields, and use of empirical treatment, as in the STAMP 
trial.8 These factors reflected differences in underlying 
tuberculosis prevalence and probability of clinicians 
starting empirical treatment based on pretest suspicion of 
tuberculosis. In addition, HIV care costs were lower in 
Malawi than in South Africa. Nonetheless, the in tervention 
was cost-effective in both countries, signalling its 
generalisability as a useful strategy in countries and areas 
with high HIV and tuberculosis burdens and varying 
resource availability.
WHO conditionally recommends TB-LAM to aid 
diagnosis of tuberculosis in hospitalised patients with HIV 
with CD4 counts of 100 cells per µL or lower and symptoms 
of tuberculosis.11 Supporting this recommendation, a 
multicountry randomised trial showed that adding 
TB-LAM in hospitalised patients with HIV and presumed 
tuberculosis significantly reduced 8-week all-cause mor-
tality.6 Some patients with HIV-associated tuberculosis 
present with atypical symptoms and would be missed by 
these criteria and the WHO testing criteria. Consistent 
with the STAMP trial results,8 we found a benefit in 
broadening the urine-based testing eligibility criteria to 
unselected hospitalised patients with HIV.
Acknowledging that selecting patients for tuberculosis 
screening by CD4 cell counts might be impractical 
because testing is often unavailable at the time of hospital 
admission, we did a subgroup comparison of the 
intervention with the standard of care among patients 
with CD4 counts less than 100 cells per µL. In the STAMP 
trial, the intervention significantly reduced mortality by 
7·1% in this group of patients (p=0·04).8 Concordantly, in 
our model-based analysis, the intervention improved 
life expectancy to a greater degree in the subgroup of 
Figure 3: 2-year and 5-year budget impact of implementing urine-based tuberculosis screening countrywide 
among all hospitalised people with HIV
SOC is sputum Xpert alone. The intervention consists of sputum Xpert, a lateral flow assay of urine for 
M tuberculosis lipoarabinomannan, and concentrated urine Xpert. The modified intervention consists of sputum 
Xpert and a lateral flow assay of urine for M tuberculosis lipoarabinomannan without urine Xpert. 
ART=antiretroviral therapy. SOC=standard of care. Xpert=GeneXpert assay for Mycobacterium tuberculosis and 
rifampicin resistance. *Includes subsequent hospitalisation.
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patients with low CD4 counts than among all patients. 
Counterintuitively, we found that the intervention was 
less economically attractive among those with low CD4 
cell counts because the costs increased to a greater degree 
than among all patients. The rise in costs associated with 
low CD4 cell counts is multifactorial and is driven largely 
by costs associated with non-tuberculosis opportunistic 
diseases and concomitant increases in ART costs due to 
improved survival.
Simulation modelling provided flexibility to examine 
alternative strategies that were not initially assessed in 
the clinical trial but that might be relevant to policy. The 
modified intervention of adding only TB-LAM to sputum 
Xpert and excluding urine Xpert was at least as cost-
effective as the trial intervention. Xpert costs substantially 
more than TB-LAM, and in the STAMP trial urine Xpert 
offered only modest incremental yield over sputum Xpert 
and TB-LAM. Being a bedside urine dipstick-type test, 
TB-LAM provides rapid results and the potential for 
starting treatment immediately.
The STAMP trial found weak evidence (p=0·07) of a 
2·8% reduction in all-cause mortality at 2 months with 
urine-based tuberculosis screening among all patients.8 
If there is truly no difference in mortality at 2 months, 
the cost-effectiveness of the intervention would be less 
robust. Even so, because of the increased diagnostic yield 
of the intervention, decreases in morbidity and mortality 
are probably realised over longer time horizons, along 
with reasonable cost-effectiveness.
Cost-effectiveness thresholds have often been tied to a 
country’s annual per-capita gross domestic product, but 
the appropriateness of this approach has been debated.32,33 
Because care guidelines in Malawi and South Africa 
include second-line ART,12,13 we compared the ICERs of the 
modelled interventions with the ICER for this treatment. 
We presumed that because comparatively expensive 
second-line ART is endorsed and financed, interventions 
that are as cost-effective might be also.32,33 Urine-based 
screening was cost-effective and the costs of the urine 
assays themselves would add little to health-care budgets. 
New diagnostics require upfront investments and can lead 
to overall higher treatment costs, and those investments 
take time to show value.34 Our analyses highlight that the 
intervention would become cost-effective by 4 years in 
Malawi and 15 years in South Africa. Our cost-effectiveness 
threshold measure was based on YLSs rather than quality-
adjusted life-years.35 Lacking country-specific preference-
based weights for all health states (especially for Malawi) in 
our model, we believed it most appropriate to use YLSs for 
consistency in outcome measures across the two countries.
Our study is subject to limitations inherent in any 
model-based analysis, including uncertainties in model 
structure and input parameters, although these mirrored 
the STAMP trial. The true prevalence of active tuberculosis 
might differ from our estimates, but our sensitivity 
analyses showed that the intervention would remain cost-
effective across a wide range of tuberculosis prevalence. 
With an effective test-and-treat strategy for HIV, the health 
and monetary value of tuberculosis screening could 
decrease, but the promise of such a strategy is far from 
reality, as shown by the number of STAMP trial participants 
without a previous HIV diagnosis or not taking ART.8,10 In 
our model we assumed imperfect but high specificity of 
Xpert and TB-LAM.4,5,25 For some tuberculosis-negative 
patients in the model the in tervention added tuberculosis 
treatment costs with little effect on life expectancy. In 
reality, false-positive tuberculosis test results might result 
in a true diagnosis of another disease being missed and 
could have a more substantial negative effect on life 
expectancy. Our model did not account for tuberculosis 
transmission. By increasing tuberculosis diagnostic yield, 
the intervention would probably reduce tuberculosis 
transmission and be even more cost-effective at a 
population level. However, without data from the STAMP 
trial to populate this parameter, we believed that excluding 
it would be a conservative approach. We did not account 
for some fixed costs such as that of an Xpert machine or a 
centrifuge for urine concentration for Xpert, although we 
did include associated increases in staff costs. Nonetheless, 
in our sensitivity analyses, diagnostic test costs had little 
effect on our findings. The STAMP trial did not use Xpert 
Ultra cartridges, which might have higher sensitivity and 
lower specificity than the conventional Xpert cartridges 
and thus might have yielded different cost-effectiveness 
results. Our budget impact analysis did not fully account 
for the logistics associated with im plementation and scale-
up of urine testing or for logistics of increasing treatment 
capacity, but we did include costs of testing and treating 
more people for tuberculosis and higher HIV-related costs 
due to longer survival. Ultimately, the results of expanding 
urine-based tuberculosis screening with scale-up might 
differ from those seen in the STAMP trial and those 
projected by our model.
Our model analysis indicated that urine-based tuber-
culosis screening with TB-LAM and Xpert in hospitalised 
patients with HIV would increase life expectancy and be 
cost-effective in resource-limited settings. We suggest that 
care guidelines in areas with high HIV burden and 
endemic tuberculosis add urine-based tuberculosis 
screening of all hospitalised patients with HIV. In 
particular we recommend the use of TB-LAM because it 
has clinical benefit, low costs, and rapid turnaround. The 
scaling-up of this strategy could help to reduce the massive 
burden of tuberculosis mortality among people with HIV 
with modest budget impact and economic efficiency.
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